Please enable JavaScript or talk to your local administrator to get JavaScript enabled.


BCG+MM Trial: Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, nonâ muscle-invasive bladder cancer: a 2-stage, randomised phase 3 trial.

Funder: National Health and Medical Research Council

Funding period
AUD 1.6 M
USD 1.1 M
Funding amount
Non-muscle invasive bladder cancer is common, causes substantial suffering and requires radical removal or irradiation of the bladder within 5 years in over 30% of people with high risk tumours despite best current treatment. Preliminary studies show exciting results from adding mitomycin (a chemotherapy drug) to best current treatment with BCG (an immunotherapy). This large randomized trial will determine the effects of adding mitomycin on cure rates, survival, side effects and quality of life.
Similar projects All >
Sorted by: Start Date
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Implication of neutrophil extracellular traps in the efficacy of bladder-sparing therapy in muscle invasive bladder cancer

Canadian Institutes of Health Research to Wassim Kassouf, Jonathan David Spicer, Ciriaco A. Piccirillo

USD 138,878
2020 - 2025
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Analysis of the antineoplastic action of Class I HDAC inhibitors to define new combination therapies for urothelial carcinoma

German Research Foundation to Günter Niegisch, Michèle Janine Hoffmann

2020 -



    1103 Clinical Sciences


    1112 Oncology and Carcinogenesis

  • RCDC


  • RCDC

    Clinical Research

  • RCDC

    Clinical Trials and Supportive Activities

  • RCDC

    Urologic Diseases




    6.1 Pharmaceuticals

  • Health Research Areas


  • Broad Research Areas

    Clinical Medicine and Science